Source comparison
Melanotan-2 Studied Erectile Dysfunction Research: Comparison
Primary Pathway MC4 receptor agonism in paraventricular nucleus → descending spinal pro-erectile signal PDE5 inhibition → increased cGMP → smooth muscle relaxation in corpus cavernosum Dopamine D2 receptor agonism in hypothalamus → central arousal signal Melan
This comparison does not assign a generated winner or score.
- Primary Pathway
- MC4 receptor agonism in paraventricular nucleus → descending spinal pro-erectile signal
- PDE5 inhibition → increased cGMP → smooth muscle relaxation in corpus cavernosum
- Dopamine D2 receptor agonism in hypothalamus → central arousal signal
- Melanotan-2 uniquely bypasses both peripheral vascular tone and dopaminergic pathways. Making it effective in populations resistant to both PDE5 inhibitors and dopamine agonists
- Onset of Action
- 2–6 hours (subcutaneous injection)
- 30–60 minutes (oral tablet)
- 20–40 minutes (sublingual)
- Slower onset limits spontaneity but extended duration (6–12 hours) may offset this in planned-activity contexts
- Response in Psychogenic Dysfunction
- 80% (Phase IIb RCT, n=1,953)
- 70–75% (meta-analysis of sildenafil trials)
- 45–55% (pooled apomorphine trials)
- Melanotan-2 shows the highest efficacy in anxiety-driven or SSRI-induced dysfunction. Where peripheral vascular tone is intact but central arousal is impaired
- Response in Organic Dysfunction
- 60% (vascular/neurogenic causes)
- 60–70% (preserved NO pathway)
- 30–40% (severely impaired cases)
- In organic dysfunction, melanotan-2 efficacy drops but remains comparable to sildenafil in men with partial nerve or vascular impairment
- Adverse Events
- Nausea (8–35% dose-dependent), flushing (15%), spontaneous erection (can occur without stimulation)
- Headache (16%), flushing (10%), visual disturbances (3%)
- Nausea (7%), dizziness (4%), syncope (rare but serious)
- Spontaneous erection is the unique risk. Men must be counselled that erections can occur in non-sexual contexts, which may be socially awkward